185 related articles for article (PubMed ID: 32624319)
1. Anaplastic thyroid carcinoma.
Yang J; Barletta JA
Semin Diagn Pathol; 2020 Sep; 37(5):248-256. PubMed ID: 32624319
[TBL] [Abstract][Full Text] [Related]
2. A relook at the 8th edition of the AJCC TNM staging system of anaplastic thyroid carcinoma: A SEER-based study.
Xiang J; Wang Z; Sun W; Zhang H
Clin Endocrinol (Oxf); 2021 Apr; 94(4):700-710. PubMed ID: 33368530
[TBL] [Abstract][Full Text] [Related]
3. Age Influences the Prognosis of Anaplastic Thyroid Cancer Patients.
Kong N; Xu Q; Zhang Z; Cui A; Tan S; Bai N
Front Endocrinol (Lausanne); 2021; 12():704596. PubMed ID: 34385977
[TBL] [Abstract][Full Text] [Related]
4. Anaplastic thyroid carcinoma: Updates on WHO classification, clinicopathological features and staging.
Abe I; Lam AK
Histol Histopathol; 2021 Mar; 36(3):239-248. PubMed ID: 33170501
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of lymph node metastasis and the eighth edition of AJCC for patients with anaplastic thyroid cancer.
Zhang H; Zhao YC; Wu Q; Wang L; Sun S
Clin Endocrinol (Oxf); 2021 Sep; 95(3):498-507. PubMed ID: 33864292
[TBL] [Abstract][Full Text] [Related]
6. Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Perrier ND; Brierley JD; Tuttle RM
CA Cancer J Clin; 2018 Jan; 68(1):55-63. PubMed ID: 29092098
[TBL] [Abstract][Full Text] [Related]
7. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why?
Tuttle RM; Haugen B; Perrier ND
Thyroid; 2017 Jun; 27(6):751-756. PubMed ID: 28463585
[No Abstract] [Full Text] [Related]
8. Noninvasive anaplastic thyroid carcinoma: report of a case and literature review.
Dibelius G; Mehra S; Clain JB; Urken ML; Wenig BM
Thyroid; 2014 Aug; 24(8):1319-24. PubMed ID: 24865498
[TBL] [Abstract][Full Text] [Related]
9. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.
Molinaro E; Romei C; Biagini A; Sabini E; Agate L; Mazzeo S; Materazzi G; Sellari-Franceschini S; Ribechini A; Torregrossa L; Basolo F; Vitti P; Elisei R
Nat Rev Endocrinol; 2017 Nov; 13(11):644-660. PubMed ID: 28707679
[TBL] [Abstract][Full Text] [Related]
10. Anaplastic thyroid cancer.
Ranganath R; Shah MA; Shah AR
Curr Opin Endocrinol Diabetes Obes; 2015 Oct; 22(5):387-91. PubMed ID: 26313900
[TBL] [Abstract][Full Text] [Related]
11. Management of Anaplastic Thyroid Carcinoma: the Fruits from the ATC Research Consortium of Japan.
Sugitani I; Onoda N; Ito KI; Suzuki S
J Nippon Med Sch; 2018; 85(1):18-27. PubMed ID: 29540641
[TBL] [Abstract][Full Text] [Related]
12. Histopathologic Features and Clinical Outcome of Anaplastic Thyroid Carcinoma with a Minor Anaplastic Component.
Wong KS; Lorch JH; Alexander EK; Marqusee E; Cho NL; Nehs MA; Doherty GM; Barletta JA
Endocr Pathol; 2020 Sep; 31(3):283-290. PubMed ID: 32445173
[TBL] [Abstract][Full Text] [Related]
13. The American Thyroid Association (ATA) integrates molecular testing into its framework for managing patients with anaplastic thyroid carcinoma (ATC): Update on the 2021 ATA ATC guidelines.
Silver Karcioglu A; Iwata AJ; Pusztaszeri M; Abdelhamid Ahmed AH; Randolph GW
Cancer Cytopathol; 2022 Mar; 130(3):174-180. PubMed ID: 34618407
[No Abstract] [Full Text] [Related]
14. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
Smith N; Nucera C
J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic Features of Mismatch Repair-Deficient Anaplastic Thyroid Carcinomas.
Wong KS; Lorch JH; Alexander EK; Nehs MA; Nowak JA; Hornick JL; Barletta JA
Thyroid; 2019 May; 29(5):666-673. PubMed ID: 30869569
[No Abstract] [Full Text] [Related]
16. Changes of Clinicopathologic Characteristics and Survival Outcomes of Anaplastic and Poorly Differentiated Thyroid Carcinoma.
Lee DY; Won JK; Lee SH; Park DJ; Jung KC; Sung MW; Wu HG; Kim KH; Park YJ; Hah JH
Thyroid; 2016 Mar; 26(3):404-13. PubMed ID: 26541309
[TBL] [Abstract][Full Text] [Related]
17. Recurrence and Survival After Gross Total Removal of Resectable Undifferentiated or Poorly Differentiated Thyroid Carcinoma.
Lee DY; Won JK; Choi HS; Park do J; Jung KC; Sung MW; Kim KH; Hah JH; Park YJ
Thyroid; 2016 Sep; 26(9):1259-68. PubMed ID: 27412715
[TBL] [Abstract][Full Text] [Related]
18. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z
Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400
[TBL] [Abstract][Full Text] [Related]
19. Methylglyoxal Acts as a Tumor-Promoting Factor in Anaplastic Thyroid Cancer.
Antognelli C; Moretti S; Frosini R; Puxeddu E; Sidoni A; Talesa VN
Cells; 2019 Jun; 8(6):. PubMed ID: 31174324
[TBL] [Abstract][Full Text] [Related]
20. Anaplastic thyroid cancer: prevalence, diagnosis and treatment.
Chiacchio S; Lorenzoni A; Boni G; Rubello D; Elisei R; Mariani G
Minerva Endocrinol; 2008 Dec; 33(4):341-57. PubMed ID: 18923370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
